JP2023509793A5 - - Google Patents

Info

Publication number
JP2023509793A5
JP2023509793A5 JP2022542364A JP2022542364A JP2023509793A5 JP 2023509793 A5 JP2023509793 A5 JP 2023509793A5 JP 2022542364 A JP2022542364 A JP 2022542364A JP 2022542364 A JP2022542364 A JP 2022542364A JP 2023509793 A5 JP2023509793 A5 JP 2023509793A5
Authority
JP
Japan
Prior art keywords
cdr
seq
optionally
complex according
nucleoside
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022542364A
Other languages
English (en)
Japanese (ja)
Other versions
JP7829488B2 (ja
JP2023509793A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/012667 external-priority patent/WO2021142234A1/en
Publication of JP2023509793A publication Critical patent/JP2023509793A/ja
Publication of JP2023509793A5 publication Critical patent/JP2023509793A5/ja
Priority to JP2026033178A priority Critical patent/JP2026102665A/ja
Application granted granted Critical
Publication of JP7829488B2 publication Critical patent/JP7829488B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022542364A 2020-01-10 2021-01-08 筋緊張性ジストロフィーを処置するための筋標的化複合体およびその使用 Active JP7829488B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026033178A JP2026102665A (ja) 2020-01-10 2026-03-03 筋緊張性ジストロフィーを処置するための筋標的化複合体およびその使用

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US202062959776P 2020-01-10 2020-01-10
US62/959,776 2020-01-10
US202062965712P 2020-01-24 2020-01-24
US62/965,712 2020-01-24
US202062968383P 2020-01-31 2020-01-31
US62/968,383 2020-01-31
US202063055499P 2020-07-23 2020-07-23
US63/055,499 2020-07-23
US202063069063P 2020-08-23 2020-08-23
US63/069,063 2020-08-23
US202063132856P 2020-12-31 2020-12-31
US63/132,856 2020-12-31
PCT/US2021/012667 WO2021142234A1 (en) 2020-01-10 2021-01-08 Muscle targeting complexes and uses thereof for treating myotonic dystrophy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026033178A Division JP2026102665A (ja) 2020-01-10 2026-03-03 筋緊張性ジストロフィーを処置するための筋標的化複合体およびその使用

Publications (3)

Publication Number Publication Date
JP2023509793A JP2023509793A (ja) 2023-03-09
JP2023509793A5 true JP2023509793A5 (cg-RX-API-DMAC7.html) 2024-01-17
JP7829488B2 JP7829488B2 (ja) 2026-03-13

Family

ID=76788870

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022542364A Active JP7829488B2 (ja) 2020-01-10 2021-01-08 筋緊張性ジストロフィーを処置するための筋標的化複合体およびその使用
JP2026033178A Pending JP2026102665A (ja) 2020-01-10 2026-03-03 筋緊張性ジストロフィーを処置するための筋標的化複合体およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026033178A Pending JP2026102665A (ja) 2020-01-10 2026-03-03 筋緊張性ジストロフィーを処置するための筋標的化複合体およびその使用

Country Status (11)

Country Link
US (1) US20230144436A1 (cg-RX-API-DMAC7.html)
EP (1) EP4087653A4 (cg-RX-API-DMAC7.html)
JP (2) JP7829488B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220125800A (cg-RX-API-DMAC7.html)
CN (1) CN115427108A (cg-RX-API-DMAC7.html)
AU (1) AU2021206234A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022013686A2 (cg-RX-API-DMAC7.html)
CA (1) CA3163295A1 (cg-RX-API-DMAC7.html)
IL (1) IL294479A (cg-RX-API-DMAC7.html)
MX (1) MX2022008533A (cg-RX-API-DMAC7.html)
WO (1) WO2021142234A1 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12370264B1 (en) 2018-08-02 2025-07-29 Dyne Therapeutics, Inc. Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
EP3830259A4 (en) 2018-08-02 2022-05-04 Dyne Therapeutics, Inc. MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
US12097263B2 (en) 2018-08-02 2024-09-24 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
WO2020028832A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US20230111212A1 (en) * 2020-01-10 2023-04-13 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
WO2021154477A1 (en) 2020-01-31 2021-08-05 Dyne Therapeutics, Inc. Anti-transferrin receptor (tfr) antibody and uses thereof
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11672872B2 (en) 2021-07-09 2023-06-13 Dyne Therapeutics, Inc. Anti-transferrin receptor antibody and uses thereof
US11633498B2 (en) 2021-07-09 2023-04-25 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
AU2021414227A1 (en) * 2020-12-31 2023-07-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
WO2023283623A1 (en) 2021-07-09 2023-01-12 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating dystrophinopathies
CA3230796A1 (en) 2021-09-01 2023-03-09 Biogen Ma Inc. Anti-transferrin receptor antibodies and uses thereof
US11833221B2 (en) 2021-09-01 2023-12-05 Ionis Pharmaceuticals, Inc. Oligomeric compounds for reducing DMPK expression
IL311507A (en) * 2021-09-16 2024-05-01 Dyne Therapeutics Inc Dosing of muscle targeting complexes for the treatment of dystrophinopathy
JP2024546436A (ja) * 2021-11-12 2024-12-24 ダイン セラピューティクス,インコーポレーテッド 顔面肩甲上腕筋ジストロフィーを処置するための筋標的化複合体およびそれらの使用
IL316143A (en) 2022-04-15 2024-12-01 Dyne Therapeutics Inc Muscle targeting complexes and formulations for the treatment of myotonic dystrophy
WO2024257848A1 (ja) * 2023-06-16 2024-12-19 ルクサナバイオテク株式会社 遅発性中枢毒性が低減されているアンチセンスオリゴヌクレオチドの設計方法、及びその製造方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2283759T3 (es) * 2002-01-18 2007-11-01 Pierre Fabre Medicament Anticuerpos anti-igf-ir y sus aplicaciones.
US20100016215A1 (en) * 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
CN104520324A (zh) * 2012-02-24 2015-04-15 施特姆森特Rx股份有限公司 Dll3调节剂及其使用方法
US9610362B2 (en) * 2012-03-16 2017-04-04 Valerion Therapeutics, Llc Antisense conjugates for decreasing expression of DMPK
JP6475167B2 (ja) * 2012-12-21 2019-02-27 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft ジスルフィド結合した多価mhcクラスiを含む多機能タンパク質
US10647768B2 (en) * 2014-05-29 2020-05-12 Macrogenics, Inc. Multi-chain polypeptide-containing tri-specific binding molecules
EP3353306A4 (en) * 2015-09-25 2019-06-05 Ionis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
DK3473270T5 (da) * 2016-06-20 2024-09-09 Genahead Bio Inc Konjugat af antistof-lægemiddel
TWI833178B (zh) * 2016-12-26 2024-02-21 日商Jcr製藥股份有限公司 通過血腦障壁之新穎抗人類運鐵蛋白受體抗體
CN118638787A (zh) * 2017-12-06 2024-09-13 艾维迪提生物科学公司 治疗肌萎缩和强直性肌营养不良的组合物和方法
AU2019315593B2 (en) * 2018-08-02 2026-05-21 Dyne Therapeutics, Inc. Muscle-targeting complexes and uses thereof
JP7858532B2 (ja) * 2020-01-10 2026-05-14 ダイン セラピューティクス,インコーポレーテッド 筋肉標的複合体および筋肉の健康に関連する遺伝子のモジュレーションのためのその使用
CN115427448A (zh) * 2020-01-10 2022-12-02 达因疗法公司 肌肉靶向复合物及其用途
CN122124274A (zh) * 2020-01-10 2026-06-02 达因疗法公司 肌肉靶向复合物及其用于治疗面肩肱型肌营养不良的用途
US20230111212A1 (en) * 2020-01-10 2023-04-13 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US20230117883A1 (en) * 2020-01-24 2023-04-20 Dyne Therapeutics, Inc. Muscle-targeting complexes and uses thereof in treating muscle atrophy
IL295022A (en) * 2020-01-31 2022-09-01 Dyne Therapeutics Inc Antibody against transferrin receptor and uses thereof

Similar Documents

Publication Publication Date Title
JP2023512442A5 (cg-RX-API-DMAC7.html)
JP2023512441A5 (cg-RX-API-DMAC7.html)
JP2023510351A5 (cg-RX-API-DMAC7.html)
JP2023535078A5 (cg-RX-API-DMAC7.html)
JP2023510350A5 (cg-RX-API-DMAC7.html)
JP2021533199A5 (cg-RX-API-DMAC7.html)
JP2025067909A5 (cg-RX-API-DMAC7.html)
JP2024501872A5 (cg-RX-API-DMAC7.html)
JP2023535073A5 (cg-RX-API-DMAC7.html)
JP2024524222A5 (cg-RX-API-DMAC7.html)
JP2024503609A5 (cg-RX-API-DMAC7.html)
JP2021533200A5 (cg-RX-API-DMAC7.html)
JP2021533197A5 (cg-RX-API-DMAC7.html)
IL316143A (en) Muscle targeting complexes and formulations for the treatment of myotonic dystrophy
IL317871A (en) Muscle targeting complexes and their uses for the treatment of FACIOSCAPULOHUMERAL muscular dystrophy
JP2024527362A5 (cg-RX-API-DMAC7.html)
JP2024525610A5 (cg-RX-API-DMAC7.html)
JP2021532832A5 (cg-RX-API-DMAC7.html)
IL309910A (en) Muscle targeting complexes and their uses for the treatment of myotonic dystrophy
IL319265A (en) Anti-transferrin receptor antibodies and their uses
JP2025512469A5 (cg-RX-API-DMAC7.html)
JP2024525611A5 (cg-RX-API-DMAC7.html)
JP2024525613A5 (cg-RX-API-DMAC7.html)
JP2024525612A5 (cg-RX-API-DMAC7.html)
JP2025512468A5 (cg-RX-API-DMAC7.html)